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Abstract
The analysis of stem cell hierarchies in human cancers has been
hampered by the impossibility of identifying or tracking tumor cell
populations in an intact environment. To overcome this limitation,
we devised a strategy based on editing the genomes of patient-
derived tumor organoids using CRISPR/Cas9 technology to inte-
grate reporter cassettes at desired marker genes. As proof of
concept, we engineered human colorectal cancer (CRC) organoids
that carry EGFP and lineage-tracing cassettes knocked in the LGR5
locus. Analysis of LGR5-EGFP+ cells isolated from organoid-derived
xenografts demonstrated that these cells express a gene program
similar to that of normal intestinal stem cells and that they propa-
gate the disease to recipient mice very efficiently. Lineage-tracing
experiments showed that LGR5+ CRC cells self-renew and generate
progeny over long time periods that undergo differentiation
toward mucosecreting- and absorptive-like phenotypes. These
genetic experiments confirm that human CRCs adopt a hierarchical
organization reminiscent of that of the normal colonic epithelium.
The strategy described herein may have broad applications to
study cell heterogeneity in human tumors.
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Introduction
Most cancers are amalgams of phenotypically distinct tumor cell
populations, which display marked differences in their behaviors
and fates. In colorectal cancer (CRC), a subpopulation of cells with
elevated tumorigenic potential expresses a gene program similar to
that of intestinal stem cells (ISCs). These ISC-like tumor cells give
rise to differentiated-like progeny, which is poorly tumorigenic
(Dalerba et al, 2007, 2011; O’Brien et al, 2007; Ricci-Vitiani et al,
2007; Vermeulen et al, 2008, 2010; Merlos-Suarez et al, 2011).
These findings have led to the notion that CRCs retain a hierarchical
organization reminiscent of that of the normal intestinal mucosa,
with only cancer stem cells being capable of self-renewal and of
sustaining long-term tumor growth (Zeuner et al, 2014). To a large
extent, this model has emerged from experiments of tumor cell
transplantation. Typically, putative stem and non-stem cell popula-
tions are isolated from patient samples using combinations of
surface markers, and then, each cell population is inoculated into
immunodeficient mice. The capacity to generate xenografts and to
reproduce some of the traits of the tumor of origin are used as read-
outs of stemness. These assays, however, only provide a snapshot
of the state of the cells in the moment they were isolated. It is also
unclear to what extent experimental manipulations influence the
tumor-initiating capacity of purified cells (Clevers, 2011). Further-
more, the requirement of antibodies against surface markers to
isolate tumor cells from patient samples imposes limitations to
explore the diversity of cell phenotypes within cancers. Alterna-
tively, the existence of tumor stem cells has been confirmed in
mouse adenomas through genetic fate-mapping experiments
(Schepers et al, 2012; Kozar et al, 2013). Yet, these lesions are
benign and contain few mutations compared to human CRCs. To
overcome these restrictions, we combined CRC patient-derived orga-
noids (PDOs) with CRISPR/Cas9 technology to label defined tumor
cell populations and perform fate-mapping experiments in vitro and
in vivo.
Results
Generation of LGR5-EGFP knock-in human CRC organoids
The expression of the Leucine-rich repeat-containing G-protein-
coupled receptor 5 (LGR5) marks adult ISCs in mice and humans
(Barker et al, 2007; Jung et al, 2011). Knock-in mice engineered to
carry EGFP and CreERT2 cassettes integrated into the LGR5 locus
have been instrumental to visualize and track ISCs in the healthy
mucosa and in tumors (Barker et al, 2007, 2009; Schepers et al,
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2012). In contrast, the analysis of LGR5+ cell populations in human
cancers has been hampered by the lack of good commercial anti-
bodies that recognize this protein at the cell surface. We thus
designed a strategy based on CRISPR/Cas9-mediated homologous
recombination to mark LGR5+ cells in human CRCs. We made use
of CRC PDOs, which are good surrogates of the disease in vitro and
in vivo (Calon et al, 2015; van de Wetering et al, 2015). For these
experiments, we initially selected a PDO derived from a stage IV
CRC that displayed a prototypical combination of genetic alterations
in major driver pathways including activation of the WNT pathway
by APC loss of function, activation of EGFR signaling by KRAS
G13D mutations, and loss of TGF-beta-mediated tumor suppression
by inactivating mutations in SMAD4 (PDO#7 in Appendix Table S1).
The targeting strategy is summarized in Fig 1A and detailed in the
Materials and Methods section. In brief, we designed Cas9 guide
RNAs complementary to sequences overlapping the stop codon of
the LGR5 locus and generated a donor vector that contained LGR5
homology arms flanking an EGFP reporter cassette positioned
immediately upstream of the stop codon. We added a LF2A self-
cleavage peptide (de Felipe et al, 2010) fused to EGFP so that
LGR5-EGFP locus was expressed as a single mRNA, whereas the
resulting polypeptide was cleaved in the two encoded proteins,
LGR5 and EGFP (Fig 1A). Next, we nucleofected organoid cells
with the donor vector together with a guide-RNA-Cas9 encoding
plasmid in a 3:1 proportion, and 48 h after, we sorted cells that had
incorporated the Cas9 vector (IRFP+ cells). About 1 in 11 IRFP+
cells expressed EGFP after 20 days in culture (Fig 1B). Subse-
quently, we generated single cell-derived organoid cultures and
assessed integration of the EGFP reporter cassette by PCR (exam-
ples in Appendix Fig S1A and B) and Southern blot (examples in
Appendix Fig S1C and D). These analyses showed that 41.7% of
the clones had correctly integrated the EGFP reporter in the LGR5
locus (Appendix Table S2). Equivalent LGR5-EGFP knock-in experi-
ments in a PDO grown from a different patient sample (PDO#6)
(Fig EV1A) rendered a frequency of correct integrations of 84.6%
(Appendix Table S2). In these single cell-derived knock-in PDO
cultures, every organoid was composed by an admixture of cells
expressing distinct EGFP levels (Figs 1C and D, and EV1B and C).
LGR5-EGFP-hi cells isolated by FACS expressed highest LGR5
mRNA levels confirming that EGFP reported endogenous LGR5
expression (Figs 1E and EV1D). Staining with KRT20 or MUC2 anti-
bodies revealed complementary expression patterns of these dif-
ferentiation markers with EGFP implying that LGR5+ CRC cells
generated differentiated progeny in vitro (Fig 1C).
To demonstrate the broad applicability of this approach, we also
engineered PDO#7 expressing TagRFP2 fused to endogenous KI67
protein (Fig 1F). The KI67 antigen is a nuclear protein which is
expressed in all active phases of the cell cycle (G1, S, G2, and mito-
sis), but is absent in resting cells (G0) (Scholzen & Gerdes, 2000). In
a previous study, knock-in mice expressing a KI67-RFP fusion
protein were used to isolate cycling (KI67-RFP+) and non-cycling
differentiated cells (KI67-RFP) from the intestinal epithelium
(Basak et al, 2014). Targeting efficiency for this knock-in construct
in human CRC organoids was similar to that observed for LGR5-
EGFP knock-in organoids (Appendix Table S2). KI67-TagRFP2 was
visualized in the nucleus of organoid cells (Fig 1G) and of xeno-
grafts derived from these organoids (Fig 1H). Cell cycle profiling of
epithelial cells isolated using FACS from dissociated xenografts
(Fig 1I) demonstrated that TagRFP2+ cells were distributed in all
cell cycle phases, whereas the TagRFP2 population was largely
enriched in cells at the G1/G0 phase (Fig 1J and K).
Characterization of human LGR5+ CRC cells in vivo
To study LGR5+ cells in vivo, we initially used an LGR5-EGFP
expressing organoid (clone #1) that by exome sequencing revealed
few acquired mutations compared to the parental population, none
of which affected known cancer driver genes (Appendix Table S3).
Clone #1 neither contained mutations in the top off-target sequences
predicted through bioinformatics for the CRISPR guide sequence
(Appendix Table S4). The LGR5-EGFP knock-in PDO was inoculated
into immunodeficient mice of the NOD/SCID strain. Xenografts
displayed a glandular organization and prominent stromal recruit-
ment. LGR5-EGFP expression labeled a substantial proportion of the
epithelial component of the tumor yet cells showed a wide range of
EGFP levels (Figs 2A and EV2). In contrast, the EGFP compartment
overlapped largely with the expression domain of the pan differenti-
ation marker KRT20+ (Fig 2B). We also observed LGR5/MUC2+
cells with goblet-like morphology intermingled between LGR5+ and
LGR5 compartments throughout the tumor (Fig 2C). These tumor
cell populations displayed equivalent distributions in xenografts
produced by a different single cell-derived clone from PDO#7
(Fig EV3A–C) or by PDO#6 (Fig EV1E–G). Overall, this cellular
organization is reminiscent of that of the normal intestinal epithe-
lium as previously proposed by several laboratories (Dalerba et al,
2011; Merlos-Suarez et al, 2011).
In flow cytometry analysis, LGR5-EGFP-high cells represented
about 3–4% of the epithelial component (EPCAM+) of dissociated
▸Figure 1. LGR5-EGFP and KI67-TagRFP2 knock-in PDOs.A Design of LGR5-EGFP donor and CRISPR/Cas9 sgRNA vectors. Blue circle represents the CRISPR/Cas9 protein complex and the yellow box underneath the guide RNA.
B Flow cytometry profiles at day 20 post-nucleofection.
C Immunofluorescence for DAPI, EGFP, and KRT20 or MUC2 in in vitro cultured PDO#7-LGR5-EGFP#1. Scale bars indicate 100 lm.
D FACS profiles showing EGFP-high (green), -low (blue), and -negative (gray) cells in PDO#7-LGR5-EGFP#1 and #2 organoids.
E Relative mRNA expression level by real-time qPCR in cells expressing distinct levels of EGFP isolated from PDO#7-LGR5-EGFP#1 and #2 knock-in organoids. Values
show mean  s.d. of three measurements.
F Design of KI67-TagRFP2 donor and CRISPR/Cas9 sgRNA vectors. Blue circle represents the CRISPR/Cas9 protein complex and the yellow box underneath the guide RNA.
G Images of PDO#7-KI67-TagRFP2#1 organoids. Scale bars indicate 100 lm.
H PDO#7-KI67-TagRFP2#1 xenograft. TagRFP2 co-localizes with DAPI nuclear staining. Scale bars indicate 25 lm.
I Flow cytometry analysis of EPCAM+/DAPI cell population of PDO#7-LGR5-EGFP/KI67-TagRFP2#1 from disaggregated xenografts.
J Cell cycle analysis of KI67-TagRFP2-positive and KI67-TagRFP2-negative cells from PDO#7-LGR5-EGFP/KI67-TagRFP2#1 disaggregated xenografts. X-axis shows DNA
content and y-axis EdU incorporation.
K Quantification of the frequencies of KI67+ versus KI67 cells found in each cell cycle phase.
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xenografts (Fig 2D). We isolated EGFP-high and EGFP-low/negative
cells by FACS (for simplicity we termed them EGFP+ and EGFP) and
analyzed their global gene expression profiles. LGR5-EGFP+ cells
expressed over 10-fold higher levels of ISC marker genes LGR5 and
SMOC2 than EGFP cells (Fig 2E). LGR5-EGFP cells expressed genes
that characterize differentiated cells of the intestinal epithelium such
as EFNB2, KRT20 or MUC2 (Fig 2E). We validated these results using
a second LGR5-EGFP knock-in clone derived from PDO#7 (Fig EV3D
and E). Microarray profiling followed by gene set enrichment analysis
(GSEA) confirmed that mouse and human intestinal stem cell gene
expression signatures were upregulated in LGR5-EGFP+, whereas
the differentiation program of colon epithelium was enriched in
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LGR5-EGFP CRC cells (Fig 2F). We next assessed the clonogenic
potential of LGR5-EGFP CRC cells. LGR5-EGFP+ cells purified from
xenografts displayed several fold higher organoid forming capacity
than LGR5-EGFP cells (Figs 2G and EV3F). Organoids generated by
LGR5-EGFP+ cells contained both EGFP+ and EGFP tumor cells in a
proportion similar to that of the PDO of origin (Figs 2H and EV3G).
We obtained similar results using LGR5-EGFP knock-in cells generated
from PDO#6 (Fig EV1H–K).
Finally, to assess the capacity of these tumor cell populations to
propagate the disease to mice, we inoculated 200 or 1,000 LGR5-
EGFP+ or LGR5-EGFP epithelial tumor cells isolated from xeno-
grafts into secondary hosts. These experiments showed that the
EGFP+ cell population was largely enriched in tumor-initiating cells
compared to their differentiated EGFP counterparts (Figs 2I and
EV3H). Tumors generated by LGR5-EGFP+ cells were populated
with stem-like (EGFP+/KRT20) and differentiated-like (EGFP/
KRT20+) tumor cells in similar proportions than the primary xeno-
grafts from which they were purified (Fig 2K) thus implying that
LGR5-expressing CRC cells undergo self-renewal and differentiation
during tumor expansion. Of note, xenografts generated by LGR5-
EGFP cell population were also formed by EGFP+ and EGFP cells
with equivalent intensities and proportions to those observed in
xenografts derived from LGR5-EGFP+ cells (Fig 2J). The expression
pattern of the differentiation markers KRT20 and MUC2 was also
similar in xenografts arising from the two cell populations (Fig 2K).
Lineage tracing of human LGR5+ CRC cells
As discussed in the introduction, currently it is not possible to
perform cell fate-mapping experiments in human cancers similar to
those performed in mouse models. To overcome this limitation, we
used CRISPR/Cas9 to engineer PDOs containing a lineage-tracing
system. We first introduced a Cre recombinase-inducible reporter
into the neutral AAVS1 locus (Fig 3A). This reporter consisted of a
constitutive Ubiquitin C (UBC) promoter driving the expression of
blue fluorescent protein mTagBFP2. This cassette was flanked by
LoxP sites so that expression of a downstream tdTomato (TOM)
reporter remains blocked until the mTagBFP2 cassette is excised by
Cre recombinase activity. Following the approach described for
LGR5-EGFP targeting, we selected long-term mTagBFP2-expressing
cells after nucleofection and expanded single cell-derived organoids.
Subsequently, we generated a second genomic edition consisting in
an LF2A-CreERT2 cassette recombined upstream of the LGR5 stop
codon (Fig 3B). The frequencies of correct integrations for these
cassettes were 47.8 and 1.78%, respectively (Appendix Table S2).
We further confirmed correct integrations of these constructs by
PCR as well as by Sanger sequencing of genomic DNA. To test their
functionality, we induced PDOs with 4-hydroxytamoxifen (4-OHT)
in vitro, which demonstrated conversion of mTagBFP2+ cells into
TOM+ cells (Figs 3C and D, and EV4A). We also tested the utility of
these constructs in vivo by inoculating double-edited PDOs in mice.
Analysis of xenografts 96 h after induction with tamoxifen revealed
the appearance of a TOM+ side population, which retained expres-
sion of LGR5 mRNA (Fig EV4B and C) supporting tracing from the
LGR5+ cell population. In contrast, we did not observe TOM+ cells
in xenografts growing in untreated mice. Based on a frequency of
about 2–4% LGR5-EGFP-hi cells in xenografts (Figs 2D and EV3D),
and on the number of TOM+ cells arising 96 h post-tamoxifen
administration (Fig EV4B), we roughly estimated that recombina-
tion occurred in 1 in every 10–20 LGR5-EGFP+ cells.
Next, we mapped the fate of LGR5+ CRC cells over an extended
period of time. The experimental setup is described in Fig 3E. In
brief, a cohort of mice bearing edited PDO-derived xenografts were
given tamoxifen once tumors were palpable. Mice were sacrificed
and tumors analyzed at the indicated time points over 28 days.
After this period, tumor pieces were transplanted into secondary
recipient mice and xenografts were analyzed for further 4 weeks.
We already observed the emergence of TOM+ individual cells scat-
tered throughout the tumor glands 96 h after tamoxifen induction
(Fig 3F). About 75% of these marks corresponded to isolated cells
and the rest to two cell clones (Fig 3G) implying that these experi-
mental conditions enable tracing from individual tumor cells. Quan-
tification of clone size revealed heterogeneity in the growth
dynamics of LGR5+ CRC cells. Whereas some clones expanded stea-
dily over time, a substantial proportion of LGR5+ divided slowly or
even remained as individual entities over extended periods (56 days
◀ Figure 2. Characterization of human LGR5+ CRC cells in vivo.A Representative images of EGFP by immunofluorescence on a section of PDO#7-LGR5-EGFP#1-derived subcutaneous xenograft. White squares indicate the position of
the insets. Scale bars indicate 1 mm for the whole xenograft and 100 lm for the insets.
B Dual immunofluorescence on paraffin sections for KRT20 and LGR5-EGFP showing complementary expression domains. Dashed line delimits expression domain in
adjacent glands. Scale bar indicates 100 lm.
C Dual immunofluorescence on paraffin sections of clone #1 for MUC2 and LGR5-EGFP. White arrows point to LGR5-EGFP/MUC2+ cells. Scale bar indicates 100 lm.
D Representative FACS profiles of EGFP+ and EGFP in EPCAM+/DAPI subpopulation from disaggregated xenografts.
E Relative mRNA expression level of intestinal stem and differentiation genes for the sorted EGFP+ and EGFP populations. Values show mean ± standard deviation
(s.d.) of three measurements.
F GSEA comparing the expression of signatures of mouse LGR5+ cells (MmLgr5-SC), human colon stem cells (hCoSCs), differentiated cells (hCo differentiation), or
proliferative crypt cells (Jung et al, 2011) in profiled LGR5-EGFP+ versus LGR5-EGFP cells.
G Representative images and quantification of organoid formation assays from cells purified from PDO#7-LGR5-EGFP#1-derived subcutaneous xenograft (n = 4 wells
per condition). Data is represented as mean ± s.d. Scale bars indicate 1 mm.
H Representative flow cytometry analysis of 15-day grown organoids from the EGFP+ and EGFP sorted populations.
I In vivo tumor initiation capacity of 1,000 and 200 sorted cells from PDO#7-LGR5-EGFP#1-derived subcutaneous xenografts. Graphs show Kaplan–Meier plots
(n = 9 xenografts).
J Distribution of the EGFP staining intensity in PDO7#1 and in xenografts derived from EGFP+ and EGFP cells. Gray line indicates background fluorescence levels.
K Dual immunofluorescence for KRT20/EGFP and MUC2/EGFP on paraffin sections of xenografts generated by EGFP+ and EGFP sorted populations respectively. Dashed
lines mark stem-like and differentiated-like compartments. White arrows point to secretory cells intermingled in the LGR5 compartment. Scale bars indicate
100 lm.
Data information: Differences in organoid formation assay were assessed with Student’s t-test and in tumor initiation assay by log-rank (Mantel–Cox) test:
*P-value < 0.05, ***P-value < 0.005, ****P-value < 0.0001. The exact P-values are specified in Appendix Table S5.
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in these experiments) (Fig 3F and G). 3D reconstruction from multi-
ple serial tissue sections confirmed the existence of many isolated
1–4 cell clones at day 28 after tamoxifen induction (Fig EV5A–D and
Movie EV1). Quantification of clone number over time showed that
the number of cells generated by LGR5+ cells was directly propor-
tional to the expansion kinetics of the tumor epithelial compartment
(Fig 3H). The scaling pattern of the LGR5+ cell output is compatible
with the hypothesis that tumor growth is largely the result of
LGR5+ cell activity. Of note, we observed few MUC2+ and KRT20+
cells in clones during the first 2 weeks of tracing, whereas the
frequency of differentiated cells increased after this period (Fig 3I
and J). Therefore, in CRC, the progeny of LGR5+ cells remains
undifferentiated during extended periods of time.
Marking of quiescent LGR5+ CRC cells
The observation that a proportion of LGR5+ cell in lineage-tracing
experiments produced few progeny may reflect a quiescent state.
Indeed, we found that about half of LGR5+ cells stained negative for
KI67 (Fig 4A and B). To further characterize this cell population, we
generated LGR5-EGFP PDOs that expressed TagRFP2 fused to
endogenous KI67 protein following the approach described in Fig 1.
Analysis of xenografts derived from LGR5-EGFP/KI67-TagRFP2
PDOs confirmed that a large proportion of LGR5-EGFP+ cells did
not express KI67-TagRFP2 (Fig 4C). In independent xenografts and
clones, the fraction of LGR5-EGFP+/KI67-TagRFP2 ranged from 20
to 50%. LGR5-EGFP+/KI67-TagRFP2 cells purified from xenografts
displayed cell cycle profiles that indicated arrest in G1/G0 phase
(Fig 4D). Using FACS, we purified KI67-TagRFP2+ (K+) and KI67-
TagRFP2 (K) cells within the LGR5-EGFP+ (L+) and LGR5-EGFP
(L) gates and compared their gene expression profiles. The L/K
cell population showed downregulation of proliferation genes,
upregulation of the cell cycle inhibitor CDKN1A, and expression of
markers of terminal differentiation KRT20 implying that they repre-
sent mature differentiated CRC cells (Fig 4E). L/K+ cells displayed
low levels of ISC marker genes and upregulated genes characteristic
of early absorptive differentiation such as FABP1 and SI (Fig 4E). By
analogy with the normal intestinal epithelium, we hypothesize that
this cell population resembles proliferative progenitors undergoing
differentiation toward an enterocyte-like phenotype. Our analysis
also showed that the L+/K cell population was characterized by
downregulation of key genes involved in proliferation and cell cycle
progression such as KI67, AURKB, FOXM1, and UBE2C (Fig 4E and
F) but retained elevated levels of ISC marker genes including LGR5
and SMOC2 (Fig 4E–G). GSEA further demonstrated an overall
downregulation of the proliferative genes in L+/K cells (Fig 4G). A
◀ Figure 3. Lineage tracing of LGR5+ CRCs in human colorectal xenografts.A Design of the donor vector containing lineage-tracing cassette and AAVS1 homology arms.
B Design of LGR5-CreERT2 donor and CRISPR/Cas9 sgRNA vectors.
C Flow cytometry analysis of double knock-in PDO#7 carrying AAVS1-LSL-TOM and LGR5-CreERT2 cassettes. Organoids were treated in vitro with 1 lM
4-hydroxytamoxifen (4-OHT). About 3.6% of the cells recombined the stop cassette (i.e., expressed low levels of mTagBFP2) and gained expression of TOM.
D Confocal imaging of double knock-in organoids 10 days after in vitro 1 lM 4-OHT addition. Scale bars indicate 50 lm. Note that recombined organoids switch
mTagBFP2 to TOM expression.
E Experimental setup used for lineage-tracing experiments.
F Representative immunohistochemistry using anti-Tomato antibodies on paraffin sections of the four time points after tamoxifen treatment. Arrowheads point to
single and two cell clones. Dashed lines delimit large clones. Scale bars indicate 250 lm.
G Clone size frequency per time point according to number of cells. Number of clones quantified was 878 for day 4, 2,424 for day 14, 6,940 for day 28, and 6,940 for
day 56.
H Correlation of number of epithelial cells per xenograft and number of cells per clone over time (n = 4 xenografts for 4 days time point, n = 5 xenografts for 14 days
time point, n = 8 xenografts for 28 days time point, n = 8 xenografts for 56 days time point).
I Expression domains of TOM and differentiation markers MUC2 and KRT20. White arrowheads indicate double-positive cells. Scale bars indicate 100 lm.
J Quantification of the number of MUC2+ and KRT20+ cells within TOM+ clones at each time point. Data is represented as the 95% confidence intervals of the
measurements. Number of clones assessed was 872 (4 days), 372 (day 14), and 69 (day 28) for KRT20 and 387 (day 4), 611 (day 14), and 130 (day 28) for MUC2. The
P-value was calculated using a generalized linear model with binomial response. ***P-value < 0.005, ****P-value < 0.0001. The exact P-values are specified in
Appendix Table S5.
Figure 4. Dual LGR5 and KI67 knock-in PDOs enable separation of quiescent and cycling LGR5+ CRC cells.
A Representative immunofluorescence image of PDO#7-LGR5-EGFP#1 stained with KI67 antibody. White arrowheads point to double-positive cells; yellow arrowheads
point to LGR5+/KI67 cells. Scale bars indicate 100 lm.
B Quantification of KI67+ cells within the LGR5+ and LGR5 compartments (n = 2,749 LGR5+ cells, 1,798 LGR5 cells assessed). Data is represented as the 95%
confidence intervals of the measurements.
C Representative FACS profiles from PDO#7-LGR5-EGFP/KI67-TagRFP2 disaggregated xenografts. Only EPCAM+/DAPI cells are shown. The four represented populations
are: LGR5-EGFP, KI67-RFP (gray), LGR5-EGFP, KI67-RFP+ (orange), LGR5-EGFP+, KI67-RFP+ (red) and LGR5-EGFP+, KI67-RFP (green).
D Cell cycle analysis LGR5-EGFP+ and KI67-RFP-positive or KI67-RFP-negative sorted populations. 5,363 and 5,398 cells were analyzed in each case.
E RT–qPCR analysis of proliferation, stem, and differentiation marker genes in the cell populations defined by EGFP/TagRFP levels. K indicates KI67, and L indicates
LGR5. Values show mean ± standard deviation (s.d.) of three measurements.
F Volcano plot representing gene expression profile of L+K+ versus L+K purified populations from LGR5-EGFP/KI67-TagRFP2 PDO#7 clone #1. Green dots indicate genes
belonging to the human colon stem cell signature, orange dots represent genes belonging to the differentiated cell signature, and blue dots depict genes of the crypt
proliferative progenitor signature. Well described genes involved in proliferation are indicated. P-values and fold changes computed by fitting a linear model with the
R package limma.
G GSEA comparing LGR5-EGFP+ cells positive or negative for KI67-RFP for the signatures used in Fig 2 as well as for signatures derived from mouse crypt LGR5-high/
KI67-high or LGR5-high/KI67-low (Basak et al, 2014). Note that the only signatures that are differentially expressed between the two populations correspond to
proliferative cells derived from either human crypts of from KI67-RFP mice. In contrast, the signature of mouse LGR5-EGFP+/KI67-RFP is significantly enriched in
LGR5-EGFP+/KI67-RFP tumor cells.
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previous work used KI67-RFP knock-in mice to show that a small
subset of LGR5+ cells in the healthy mucosa downregulate the
expression of KI67 (Basak et al, 2014). We used transcriptomic data-
sets from these mice to identify genes up- and downregulated in
normal LGR5+/KI67+ and LGR5+/KI67 crypt cells (Basak et al,
2014). Our analyses showed striking enrichment of these gene sets
in L+/K+ versus L+/K CRC cells (Fig 4G). In contrast, the oncoge-
nes MYC and MYB, the expression of which is driven by the WNT
pathway in CRC (van de Wetering et al, 2002), remained elevated in
quiescent and proliferating LGR5+ tumor cell populations (Fig 4E).
Discussion
The combination of organoid and CRISPR/Cas9 technology described
herein opens up the study of human tumors through genetic
approaches that had only been feasible in animal models. This
advance is particularly well suited to analyze phenotypic diversity of
cell populations within cancers as it enables labeling and tracing of
distinct tumor cells through specific marker genes, which are not
necessarily expressed at the cell surface. In contrast, its utility to study
genomic heterogeneity is limited, as the current method requires
cloning of individual tumor cells to guarantee the accuracy of the
genomic insertions. Therefore, tumors generated from edited orga-
noids reflect the behavior of a single stem cell lineage in a genetically
homogenous mutational background. To ensure that edited organoids
are good surrogates of the parental population, we selected those
displaying mutational profiles that overlapped with that of the orga-
noid of origin. Still, although unlikely, we cannot rule out that the few
private mutations identified in these monoclonal organoids or other
epi-genetic alterations may confer differential properties. Despite
these caveats, the possibility of performing cell fate-mapping experi-
ments in human cancers represents a substantial advance. For the
first time, this approach enables the analysis of cell lineage relation-
ships in intact tumors and will help address how distinct cell popula-
tions contribute to growth, dissemination and resistance to therapy.
Colorectal cancer stem cells had been previously isolated from
patient samples using distinct surface markers including CD44,
CD133, or EPHB2, which enrich in populations of tumor-initiating
cells (O’Brien et al, 2007; Dalerba et al, 2007; Ricci-Vitiani et al,
2007; Merlos-Suarez et al, 2011). In normal colonic mucosa, these
markers are expressed broadly throughout the stem and transient
amplifying compartments (Zeilstra et al, 2008; Snippert et al, 2009;
Jung et al, 2011). In contrast, the expression domain of LGR5 is
restricted to ISCs (Barker et al, 2007) yet the analysis of LGR5-
expressing cells in human CRCs had not been possible due to the
lack of good reagents. Our work shows that human LGR5+ CRC cells
express the gene program of normal ISCs, are clonogenic ex vivo,
and display robust tumor-initiating capacity in xenograft assays. We
also performed for first time experiments of lineage tracing in
human CRC, which demonstrate that LGR5+ tumor cells produce
progeny over long periods of time, which undergo differentiation to
distinct lineages. Hence, our work reinforces the notion that despite
the accumulation of multiple genetic alterations, human CRCs are
governed by a cell hierarchy reminiscent of that present in the
normal intestinal epithelium. Our observations revealed two other
interesting aspects. First, the kinetics of differentiation of tumor cells
in CRC appears to be a relatively slow process compared to the
normal epithelium, where the progeny of LGR5+ ISCs undergoes dif-
ferentiation 2–3 days after they leave the crypt base (Clevers, 2013).
In contrast, clones produced by LGR5+ CRC cells were largely
devoid of differentiated cells, which only started to accumulate after
2 weeks approximately. This delayed differentiation fits in well with
the observation that LGR5+ and KRT20+ tumor cells reside in
complementary compartments rather than intermingled in the same
area and may suggest that distinct tumor niches facilitate stem or
differentiation states. Second, whereas the vast majority of normal
ISCs remain in a proliferative state (Schepers et al, 2012; Basak
et al, 2014), a substantial proportion of LGR5+ CRC cells contribute
with few progeny according to the lineage-tracing data. This subset
of inactive LGR5+ cells likely represent LGR5+/KI67 cells identi-
fied in double-reporter knock-in PDOs. These data further support
previous clonal analysis of CRC using lentiviral marking of patient
samples, which revealed the existence of dormant cells that can be
reactivated upon passaging or chemotherapeutic treatment (Dieter
et al, 2011; Kreso et al, 2013). Finally, the finding that the progeny
of LGR5+ tumor cells scales with the total number of epithelial cells
fits in well with the hypothesis that CRC growth is the result of the
activity of multiple LGR5+ tumor stem cells. Nevertheless, our data
does not rule out that LGR5 cells could contribute equally to tumor
growth. In the normal intestinal epithelium, differentiated cells can
opportunistically replace LGR5 + ISCs through plasticity (van Es
et al, 2012; Tetteh et al, 2016), implying that the ISC phenotype is
not hardwired but rather is induced by the niche. Thus, it is likely
that LGR5+ and LGR5 tumor phenotypes are also plastic. Our
observation that the xenografts generated by LGR5 cells display
cellular patterns equivalent to those produced by LGR5+ cells may
indicate interconversion of the two cell populations in these
transplantation assays, yet confounding effects such as suboptimal
isolation of the LGR5-EGFP population could as well explain our
results. Proper assessment of cell plasticity will require mapping the
fate of LGR5 cells in intact tumors through genetic strategies equiv-
alent to those described herein.
Materials and Methods
Organoid cultures
PDO#6 and PDO#7 have been previously described (Calon et al,
2015). In brief, the tumor sample used to expand PDO#6 was obtained
from an individual treated at Hospital de la Santa Creu i Sant Pau,
under informed consent and approval of the Tumor Bank Committees
according to Spanish ethical regulations. The study followed the
guidelines of the Declaration of Helsinki, and patient identity for
pathological specimens remained anonymous in the context of this
study. Tumor cells were grown as organoids embedded in BME2
(basement membrane extract 2, AMSbio) using a modification of the
media described by the Clevers laboratory (van de Wetering et al,
2015) (Advanced DMEM/F12, 10 mM HEPES, 1× Glutamax; 1× B-27
without retinoic acid, 20 ng/ml bFGF (basic fibroblast growth factor);
50 ng/ml EGF (epidermal growth factor), 1 lM LY2157299, 10 lM
Y27632, and recombinant Noggin (100 ng/ml). PDO#7, a kind gift
from G. Stassi (University of Palermo), was obtained from the dissoci-
ation of whole CRCs in suspension as described elsewhere (Lombardo
et al, 2011). Upon arrival to our laboratory, they were cultured with
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the medium described above. All cells were tested weekly for myco-
plasma contamination with negative results.
Xenograft assays
All experiments with mouse models were approved by the Animal
Care and Use Committee of Barcelona Science Park (CEEA-PCB) and
the Catalan government. We inoculated 150,000 cells (PDO#7) or
2 million cells (PDO#6) in a format of 5- to 7-day grown organoids
subcutaneously into NOD/SCID female mice in 50% BME2-HBSS.
Generally, a maximum of 4 xenografts were generated per animal.
Tumor volume was measured with manual calipers. For tumor initi-
ation assays, viable single human cells (EPCAM-positive; DAPI-
negative) from disaggregated xenografts were sorted according to
their EGFP levels and subsequently transplanted into recipient mice
in 100 ll of BME2:HBSS (1:1).
Lineage tracing and clonal analysis
Cohorts of NOD/SCID mice were inoculated with organoids as
described above. When tumors were palpable, mice were given two
consecutive doses of tamoxifen (250 mg/kg) to maximize recombi-
nation. Mice were sacrificed at indicated time points and tumors
were processed for histological analysis. Clone sizes over time were
determined in histological sections and scored by manual counting
or image analysis software. We averaged measures from distinct
sections and xenografts at each time point. Size of clones present at
4-day post-tamoxifen induction was assessed manually. For subse-
quent time points, we analyzed images using Interactive Learning
and Segmentation Toolkit, Ilastik software (www.ilastik.org). We
set the algorithm parameters so that adjacent clones or cells that
were not in contact computed as independent clones. A full descrip-
tion of the methodology used for clonal analysis is included in the
Appendix Supplementary Methods.
Transcriptomic profiling
RNA from selected tumor cell populations isolated from xenografts
by FACS (1,000–5,000 cells per sample) was amplified using pico-
profiling (Gonzalez-Roca et al, 2010) and subsequently hybridized
on Primeview arrays (Affymetrix). Gene expression was analyzed
using standard methodology as described in the Appendix Supple-
mentary Methods. Data have been deposited at Gene Expression
Omnibus (GSE92960 and GSE92961).
A detailed description of the methods is included in the
Appendix Supplementary Methods.
Expanded View for this article is available online.
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